Implant Tribune

The World's Dental Implant Newspaper · U.S. Edition

September 2009 www.implant-tribune.com Vol. 4, No. 9

Materialise's new product
With new SimPlant software, you get 'Crystal' clear results

▸Page 2B

New ITI president
International Team for Implantology has new leader

▸Page 6B

Astra setting standards
System helps optimize marginal bone maintenance

▸Page 17B

AAID: Why save bad teeth? Dental heroics unnecesary

Dental implants increasingly preferred

For years, it was common practice for dentists to perform repeat root canals and other procedures to save teeth compromised by extensive decay, gum disease and bone loss. Today, the American Academy of Implant Dentistry (AAID) said times have changed and patients should forego prolonged dental heroics to save failing teeth and replace them with long-lasting dental implants.

"There really is no justification for undergoing multiple endodontic or periodontic procedures, and enduring the pain and financial burden, to save a diseased tooth," said John Minichetti, DDS, speaking for the AAID. "The days are over for saving teeth till they fall out. Preserving questionable teeth is not the best option from both oral health and cosmetic perspectives."

Losing a tooth is an emotional decision and patients must clearly understand the oral health and cosmetic implications of preserving questionable teeth. Even

→IT page 4B

JOP study compares alveolar bone reconstruction methods

Endosseous implants fare equally well after either distraction osteogenesis or autogenous bone grafting, according to a new report published in the September 2009 issue of the Journal of Oral Implantology.

Following alveolar reconstruction, endosseous implants support and retain the prosthesis.

Therefore, it is important for the method of alveolar reconstruction to be highly compatible with the subsequent implantation.

The authors conducted a retrospective analysis to determine whether distraction osteogenesis or autogenous bone grafting offers a greater chance of clinical success.

The authors included 82 consecutive patients from the patient population of Loma Linda University in a retrospective analysis of the two alveolar reconstruction techniques and the subsequent endosseous implantation.

All patients had been evaluated for implant success in a 36- to 61-month follow-up. Implants preceded by autogenous bone grafts had a success rate of 97 percent, and those preceded by distraction osteogenesis had a success rate of 98 percent. There was no statistical difference between the two methods.

To read the entire article, "Implant Success in Distracted Bone Versus Autogenous Bone-Grafted Sites," visit: *http://www2.allenpress.com/pdf/orim-35-04-196-200.pdf*

About the Journal of Oral Implantology

The Journal of Oral Implantology is the official publication of the American Academy of Implant Dentistry and of the American Academy of Implant Prosthodontics. It is dedicated to providing valuable information to general dentists, oral surgeons, prosthodontists, periodontists, scientists, clinicians, laboratory owners and technicians, manufacturers and educators. The JOI distinguishes itself as the first and oldest journal in the world devoted exclusively to implant dentistry.

To learn more about the American Academy of Implant Dentistry, visit *www.aaid-implant.org/index.html.* IT

ICOI's World Congress XXVI in Canada

By Sierra Rendon, Managing Editor

It was a weekend of learning and growing at the International Congress of Oral Implantologists (ICOI) World Congress XXVI, 12th annual IPS Symposium and 12th Congress of the Asia

→IT page 8B



Dr. Natalie Wong speaks on 'Destination ... Digital! From Plans, Scans and Now, Digital Impressions' at the ICOI World Congress in Vancouver.

AD

Materialise Dental launches SimPlant Crystal

Materialise Dental has launched its latest software version: SimPlant® Crystal.

With SimPlant Crystal, clinicians obtain crystal clear images from CT and cone-beam scanners, resulting in even better implant treatment planning. And that's not all. SimPlant Crystal now also provides a link to DentalPlanit®, a brand new Web site where clinicians can collaborate 24/7 with local imaging centers and other partners to quick start their case planning.

When it comes to implant treatment planning, clinicians need images of unrivaled clarity to work with. SimPlant Crystal gives clinicians high-definition images, originating from CT and cone-beam scanners, hence offering even more accurate bone density evaluation and allowing for easier identifica-

→ IT page 6B

SimPlant Crystal offers practitioners unrivaled clarity.

AD

Are your patients waiting for their molars?

Immediate implant placement in a molar socket.

MAX Dental Implant System

SOUTHERN IMPLANTS

Southern Implants Corporate Office
5 Holland Building 209 Irvine, CA 92618 Toll Free 866 700-2100 Tel 949 273-8505
www.southernimplants.us ©2009 Southern Implants Inc. All rights reserved.

Please visit us at
Booth #347

IMPLANT TRIBUNE
The World's Newspaper of Implantology · U.S. Edition

Publisher & Chairman
Torsten Oemus
t.oemus@dental-tribune.com

Vice President Global Sales
Peter Witteczek
p.witteczek@dental-tribune.com

Chief Operating Officer
Eric Seid
e.seid@dental-tribune.com

Group Editor & Designer
Robin Goodman
r.goodman@dental-tribune.com

Editor in Chief
Sascha A. Jovanovic, DDS, MS
sascha@jovanoviconline.com

Managing Editor/Designer
Implant & Endo Tribunes
Sierra Rendon
s.rendon@dental-tribune.com

Managing Editor/Designer
Ortho Tribune & Show Dailies
Kristine Colker
k.colker@dental-tribune.com

Online Editor
Fred Michmershuizen
f.michmershuizen@dental-tribune.com

Account Manager
Humberto Estrada
h.estrada@dental-tribune.com

Marketing Manager
Anna Wlodarczyk
a.wlodarczyk@dental-tribune.com

Marketing & Sales Assistant
Lorrie Young
l.young@dental-tribune.com

C.E. Manager
Julia Wehkamp
j.wehkamp@dental-tribune.com

Dental Tribune America, LLC
213 West 35th Street, Suite 801
New York, NY 10001
Phone: (212) 244-7181, Fax: (212) 244-7185

BPA WORLDWIDE BUSINESS

Published by
Dental Tribune America

© 2009, Dental Tribune International GmbH. All rights reserved.

Dental Tribune makes every effort to report clinical information and manufacturer's product news accurately, but cannot assume responsibility for the validity of product claims, or for typographical errors. The publishers also do not assume responsibility for product names or claims, or statements made by advertisers. Opinions expressed by authors are their own and may not reflect those of Dental Tribune International.

Editorial Advisory Board

Dr. Sascha Jovanovic, Editor in Chief
Dr. Bernard Touati
Dr. Jack T. Krauser
Dr. Andre Saadoun
Dr. Gary Henkel
Dr. Doug Deporter
Dr. Michael Norton
Dr. Ken Serota
Dr. Axel Zoellner
Dr. Glen Liddelow
Dr. Marius Steigmann

ACE
SURGICAL SUPPLY CO., INC.

Osteocel®

osteoGENESIS
osteoINDUCTION
osteoCONDUCTION

The Future Is Now.

For more information or to place an order call 800.441.3100

www.acesurgical.com
ACE Surgical Supply Company, Inc. • 1034 Pearl Street, Brockton, MA 02301

Before: exposed implant

Osteocel bone graft in place prior to mesh fixation

4 months: After mesh removal

Ridge Augmentation clinical case.

A Bone Matrix Product Containing Stem Cells.

The Properties of Autograft without Associated Risks

The proprietary processing technology that produces Osteocel® results in a viable bone matrix product that preserves the native stem cells found in marrow rich bone. It is the only product available today that has the desired beneficial properties of autograft - osteoconduction, osteoinduction and osteogenesis – and that allows surgeons to provide their patients with optimal bone growth conditions without the added risk and cost of a secondary procedure.

Low Immunogenicity

Mesenchymal stem cells are IMMUNE-PRIVILEGED cells that do not stimulate a cellular immune response. Osteocel does not activate T cell proliferation, as shown *in vitro* from Mixed Lymphocyte Reaction (MLR) testing.

Histologic Evidence

Positive clinical use of Osteocel since 2005 demonstrates bone-forming ability. Histology from a human sinus augmentation study using Osteocel shows substantial vital bone content at 16 weeks, with very low residual graft material.[1]

Bone Formation

Stem cells contained in Osteocel are capable of differentiating into bone cells. Every lot of Osteocel is tested for bone forming potential.

Viable Cell Content

The osteogenic potential arises from the stem cells in Osteocel. Following processing of marrow-rich bone, release testing demonstrates osteogenic potential according to the following criteria:

- Rich supply of stem cells: Greater than 50,000 cells/cc
- Viability: Greater than 70% cell viability
- Positive osteogenesis: In vitro cell culture assay

[1] Histologic Evaluation of a Stem Cell Based Sinus Augmentation Procedure: A Case Series. – McAllister, Haghighat, Gonshor. – Journal of Perio., April 2009

ADVANCED TISSUE GRAFTING
2-DAY HANDS-ON CADAVER WORKSHOP

BOSTON
October 2009

LAS VEGAS
December 2009

For more details or to register go to www.acesurgical.com/cadaver.html

Limited availability. Last 2 courses sold out! Reserve your space by registering today.

AD

← IT page 1B

though patients often resist losing natural teeth, in many cases the best outcomes occur from extracting them and inserting implants, which look and function like natural teeth.

"Our patients expect restorative dental procedures to make their smiles more attractive and long-lasting. In most cases, implants deliver the best results, as the ultimate goal is to achieve an esthetic and functional restoration for years to come," Minichetti said.

Published studies have shown there is a higher failure rate of root canal procedures vs. dental implants.

In some cases, root canals fail because abscesses occur, and oral surgery is required to clean out the infected area.

Minichetti noted that a recent study published in the *Journal of Oral Implantology* showed that single-tooth dental implants are 98.5 percent successful after seven years and there was no discernable bone loss in almost all the implant sites.

First-time root canals fail 5 percent of the time, according to the American Academy of General Dentistry, and at much higher rates in repeat procedures. Further, endodontic surgical re-treatments, according to published studies, have success rates ranging from 37 to 87 percent.

Saving compromised teeth in the esthetic zone with periodontal treatments also can have unfavorable cosmetic results, according to Minichetti.

"Periodontal procedures to save decaying natural teeth can require raising the gum line and exposing teeth roots to anchor a new crown," he said. "The crown needs something to hold onto, so you have to push the gum tissue up with unfavorable cosmetic impact."

He noted that patients should always ask the dentists how their smiles will look if they chose to save a questionable tooth in the esthetic zone with a periodontal procedure.

AAID is based in Chicago and has more than 3,500 members. It is the first organization dedicated to maintaining the highest standards of implant dentistry by supporting research and education to advance comprehensive implant knowledge.

(Source: AAID)

AD

PIEZOSURGERY®

ORIGINAL • PATENTED • PROVEN

12 Years Clinical Research | **30+** US & International Patents | **50+** Surgical Insert Tips | **75+** Published Articles & Studies



Bone Block Harvesting

Bone Chips Harvesting

Crown Lengthening

Apicoectomy

Impacted Tooth Extraction



Orthodontic Microsurgery

Ridge Expansion

Periodontics

VISIT US AT
AAP
BOOTH
#1046

Sinus Lift



Implant Site Preparation

Atraumatic Tooth Extraction

If you are cutting bone... you need PIEZOSURGERY®!

Find out what Piezosurgery® can do for you!

CONTACT

1.888.87.PIEZO
7 4 3 9 6

www.piezosurgery.us

Dr. Daniel Buser elected ITI president

The International Team for Implantology, an academic organization dedicated to the promotion of evidence-based research and education in the field of implant dentistry, has announced the election of Prof. Daniel Buser (Bern, Switzerland) as its new president.

The elections were held at the ITI's annual general meeting 2009 in Copenhagen.

Buser has been an ITI fellow since 1986 and has taken an active role in the organization's running since that time.

He has been a member of various ITI committees, most recently chairman of the education committee, as well as serving on the ITI Board of Directors.

In 2007, he was nominated president-elect. Buser follows outgoing president Prof. Dieter Weingart (Stuttgart, Germany), who led the organization from 2005 to 2009. Weingart will assume the role of past president, and will continue to serve on the ITI Board until 2011.

"Dr. Buser is an excellent educator and a charismatic leader," Weingart said. "His contribution to the ITI, particularly in matters of education, is vast and his dedication complete. I am confident that both the ITI and the entire field of implant dentistry will greatly benefit from his term of office as ITI president."

Buser is an oral surgeon and professor and chairman at the Department of Oral Surgery and Stomatology, as well as executive chairman of the School of Dental Medicine at the University of Bern, Switzerland.

He has authored and co-authored more than 200 publications and book chapters, and is also a driving force behind the ITI Treatment Guide series.

"I am excited to take on my new role as ITI president, and I look forward to working with the ITI Board of Directors to further establish the ITI as the leading academic organization in the field of implant dentistry," Buser said.

"Our main focus in the upcoming four years of my presidency will be on quality assurance through best-in-class education, the efficient implementation of the recently established ITI University Program, on strengthening the ITI's independence, as well as increasing ITI activities at a national level through our country sections."

Professor Daniel Buser is the new president of the International Team for Implantology.

Buser received his undergraduate and postgraduate degrees in dentistry from the University of Bern. He did research at the Harvard School of Dental Medicine in Boston from 1989 to 1991, and spent educational sabbaticals at the Baylor College of Dentistry in Dallas in 1995, as well as at the University of Melbourne, Australia from 2007 to 2008.

His main scientific interests are in the field of tissue integration of dental implants, the bone-implant interface, bone regeneration in defect sites, guided bone regeneration, autografts and bone substitutes, as well as long-term studies on dental implants.

In addition to his work for the ITI, Buser served as president of the European Association for Osseointegration from 1996 to 1997, was president of the Swiss Society of Oral Implantology from 1999 to 2002 and was president of the Swiss Society of Oral Surgery and Stomatology from 2002 to 2007.

He is also president of the Board of the Swiss Implant Foundation and a board member of the Osteology Foundation. IT

← IT page 2B

AD



tion of anatomical structures.

Needless to say, it's always imperative to be able to work in a time- and cost-efficient environment. SimPlant Crystal links to DentalPlanit, a new online collaboration tool allowing clinicians to collaborate with various imaging centers in their patient's neighborhood and other partners.

At just the click of a button, DentalPlanit delivers patient images and treatment cases 24/7 and straight onto the clinician's computer.

In short, SimPlant Crystal helps clinicians work more efficiently and expand their business.

It gives them the freedom and flexibility to work on their patient's cases whenever they want to and wherever they are — and providing them fast and round-the-clock service. Last but not least, it gives them the means to communicate with their patients in a visually clear way.

SimPlant Crystal is all about predictable and accurate dental implant treatment, resulting in a more efficient and stress-free practice.

From scan to plan to guide, to the ultimate Immediate Smile®, SimPlant Crystal gives clinicians the opportunity to plan their surgery time more efficiently, accept more referrals and enjoy a higher revenue on even the most complex cases.

It also allows them to continue working with the implant brands and scanning equipment they already know and use. SimPlant Crystal is compatible with them all, and thus, suits clinicians' ways of working.

For more information, please contact Materialise Dental at (443) 557-0121 or e-mail *simplant@materialise.com.* IT

(Source: Materialise Dental)

Tell us what you think!

Do you have general comments or criticism you would like to share? Is there a particular topic you would like to see more articles about? Let us know by e-mailing us at ***feedback@dental-tribune.com***. If you would like to make any change to your subscription (name, address or to opt out) please send us an e-mail at ***database@dental-tribune.com*** and be sure to include which publication you are referring to. Also, please note that subscription changes can take up to 6 weeks to process.

Time to challenge old truths

Astra Tech Implant System™ – setting a new standard

How do you achieve optimal long-term treatment outcomes for your patients? The standard norm regarding dental implant treatment success from 1986 does not reflect what is possible to achieve today. There are no reasons why the clinician or the patient should accept a marginal bone loss of up to 1.5 millimeters based on a standard set 20 years ago. It has been proven in study after study that with the Astra Tech Implant System™ the mean marginal bone level reduction is only 0.3 millimeters over five years.



* Astra Tech Implant System™ level based on data from more than 40 published articles presenting radiological data; literature search April 2008

** Standard norm according to:
Albrektsson T., et al., Int J Oral Maxillofac Implants 1986;1(1):11-25
Albrektsson T. and Zarb G.A., Int J Prosthodont 1993;6(2):95-105
Roos J., et al., Int J Oral Maxillofac Implants 1997;12(4):504-514

Visit us at booth #1001 at the AAP Meeting.

ASTRA TECH DENTAL
Get inspired

WHY SETTLE FOR LESS?

ASTRA TECH

A company in the AstraZeneca Group

800-531-3481. www.astratechdental.com

← IT page 1B

Pacific Section in Vancouver from Aug. 20-22.

Beyond the teaching and the exhibits, relationships were continually exhorted as a key part of membership in the ICOI.

"More than education, we developed friendship and relationships," said Dr. Scott Ganz, session host and speaker. "Camaraderie is a very important part of the ICOI experience."

Dr. Jack Krauser who spoke on "Guided Implant Surgery: The Good, the Bad and the Ugly," agreed with Ganz.

"We love implant dentistry," he said. "Throughout 20 years in ICOI, I've made wonderful friends from across the world."

Despite encouragement to take time to cultivate friendships, education was the focus of the event. The theme was "Defining New Paradigms in Implant Dentistry: Interdisciplinary Concepts for Success."

A sampling of speakers included:

• Dr. Renzo Casellini who spoke on "Esthetics in Three Dimensions: Simple, Fast and Predictable." Casellini offered information on the newest techniques in zirconium abutments, over structures, crowns and full screw-retained restoration in zirconium with white and pink porcelain esthetics. "Success is a team approach," he said.

ICOI World Congress attendees focus on the Main Podium. (Photo by Sierra Rendon/Implant Tribune)

"We really have a team, including the patient. Teamwork means success for these cases. No one can do it alone. We need to work together."

• Ganz (also session host) who spoke on "The Impact of Digital Dentistry on Prosthetic Paradigms." Ganz led the audience to understand how to utilize technology in predicting implant placement and matching implant design with available anatomy, or in anticipation of bone grafting procedures. "New paradigms can truly help us to plan our cases and treatment better," he said.

• Dr. Natalie Wong who spoke on "Destination … Digital! From Plans, Scans and Now, Digital Impressions." Wong traced the history and evolution of digital implant dentistry and offered suggestions on integrating and utilizing technology within practices. Her opinion is that the next phase of implant dentistry in the digital revolution will be digital impression making. Her components of an ideal digitable impression included: allows ability to scan quadrant to full arches; allows for fabrication of all types of dental restorations; allows for subgingival preparation; and allows lab users to export digital case data to file formats supported by CAD/CAM manufacturers.

• Dr. Michael Pikos who spoke on "Sinus Grafting in the Presence of Cysts and Polyps." Pikos explained how to assess the presence, size and location of maxillary sinus polyps and mucous retention cysts and offered a treatment protocol for removing maxillary sinus polyps and mucous retention cysts simultaneously with sinus augmentation surgery. He advocated the use of cone-beam technology as well, stating: "None of this can happen without cone-beam technology."

Speakers and attendees raved about the Vancouver event and the quality of the educational program.

"You have been subject to some wonderful speakers, and I'm pleased to be a part of this," Pikos said. "This organization is especially meaningful to me personally because it's where I began speaking many, many years ago."

For more information about ICOI events, go to *www.icoi.org*. IT

Coming soon

Look for an interview with Dr. Kenneth W. M. Judy, co-chairman of the ICOI, in next month's Implant Tribune.

AD

BioHorizons to host congress

BioHorizons is one of the fastest growing oral reconstructive device companies in the world.

Highly advanced implant technologies, lifetime warranty, regeneration products and strong commitment to continuing education have placed BioHorizons at the forefront of implant dentistry since 1997.

Cascais, near Lisbon, Portugal, is the location for the BioHorizons European Congress 2009, "Pathways to Patient Satisfaction," which will take place Oct. 9–10.

This year's program features a lineup of renowned international speakers addressing current trends in implant dentistry and tissue regeneration with a special focus on satisfying, and exceeding, patient expectations.

In addition to the lectures, hands-on workshops will provide an opportunity for training on new techniques, and a gala dinner will offer a chance to socialize with colleagues and the presenters.

Enrollment will be limited to maintain an environment conductive to learning, so register now to reserve your place at this event.

- ***Venue:*** Mirage Hotel Cascais
- ***Registration fee:*** 495€. Includes main program, coffee breaks, lunches and Gala Dinner Saturday night. Companions may attend the Gala Dinner for an additional 50€.
- ***Price per room per night (single):*** 160€
- ***Price per room per night (double):*** 180€. This is a special price only available for this event. The hotel will maintain this price five days before and after the event. Breakfast is included.
- ***Airport:*** Lisbon Airport (LIS) is the closest international airport, 25 km from the hotel.
- ***Information and registration:***

E-mail:
EuroCongress09@biohorizons.com
Phone: +34 91 713 1084
Fax: +34 91 355 83 75

AD

Nobel Biocare™

NobelActive™

Taking a new direction in implants.

Dual-function prosthetic connection

Bone-condensing property

Adjustable implant orientation for optimal final placement

Built-in Platform Shifting™

High initial stability, even in compromised bone situations

10 YEARS WITH TIUNITE® SURFACE
New data confirm long-term stability.

NobelActive equally satisfies surgical and restorative clinical goals. NobelActive thread design progressively condenses bone with each turn during insertion, which is designed to enhance initial stability. The sharp apex and cutting blades allow surgical clinicians to adjust implant orientation for optimal positioning of the prosthetic connection. Restorative clinicians benefit by a versatile and secure internal conical prosthetic connection with built-in Platform Shifting upon which they can produce excellent esthetic results. Based on customer feedback and market demands for NobelActive, the product assortment has been expanded – dental professionals will now enjoy even greater flexibility in prosthetic and implant selection.
Nobel Biocare is the world leader in innovative evidence-based dental solutions.
For more information, contact a Nobel Biocare Representative at 800 322 5001 or visit our website.

www.nobelbiocare.com/nobelactive

Nobel Biocare USA, LLC. 22715 Savi Ranch Parkway, Yorba Linda, CA 92887; Phone 714 282 4800; Toll free 800 993 8100; Tech. support 888 725 7100; Fax 714 282 9023
Nobel Biocare Canada, Inc. 9133 Leslie Street, Unit 100, Richmond Hill, ON L4B 4N1; Phone 905 762 3500; Toll free 800 939 9394; Fax 800 900 4243
© Nobel Biocare 2009. All rights reserved. www.nobelbiocare.com